US EditionPresident Trump Unveils Deal to Expand Coverage, Lower Costs on GLP-1 Obesity Drugs Like Wegovy
The deal will expand Medicare coverage and cut costs for GLP-1 obesity drugs, addressing affordability barriers faced by over 75% of patients, officials said.
- On Thursday, President Donald Trump unveiled a deal with Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for Zepbound and Wegovy, with Medicare coverage starting next year.
- Facing pressure over prices, the White House moved to broaden insurance coverage for obesity treatments after Tuesday's elections, where high-priced GLP-1 obesity drugs costing about $500 monthly limited access, the administration said.
- Starting with price details, pill versions would cost $149 a month if approved, Lilly cut initial Zepbound doses to $349 earlier this year, and the TrumpRx program offers $50 copays with phased lower prices for uninsured.
- In the Oval Office, Trump framed the deal as a health benefit, with Robert F. Kennedy, Jr. saying `Trump is the friend of the forgotten American` at Thursday's announcement.
- Officials warned the consumer impact of price cuts remains uncertain, though the deal also extends lower prices to state and federally funded Medicaid programs.
27 Articles
27 Articles
Trump official says Americans will lose ’135 billion’ pounds by 2026 midterms
Dr. Mehmet Oz was front and center Thursday as President Donald Trump unveiled a new deal with two pharmaceutical giants to expand coverage and reduce prices for their popular obesity treatments.
Trump Unveils Deal to Expand Coverage for 'Fat Drug'
President Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices...
By Tami Luhby and Meg Tirrell, CNN — Certain popular obesity medications will be available for as little as $149 a month, and more Medicare beneficiaries will have access to them under two deals announced Thursday by the Trump administration. The agreements with Eli Lilly and Novo Nordisk, which President Donald Trump previewed in remarks last month, are the administration's latest effort to lower drug prices. As part of these new agreements, th…
Trump administration announces deal for GLP-1s under Most Favored Nation policy
(The Hill) — The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk's Wegovy and Lilly’s Zepbound, for a [...]
Trump Announces Deal With Weight-Loss Drug Manufacturers for Medicaid and Medicare Patients
Mark Schiefelbein/APTwo pharmaceutical companies agreed to lower the price of their blockbuster weight loss drugs, as well as other medications, in exchange for limited Medicare coverage and in an effort to comply with the Trump administration’s demands for a “most-favored-nation” drug pricing structure, the president announced on Thursday.“You think it was easy dealing with these people? It wasn’t,” Trump said from the Oval Office. “Nobody else…
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
